Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Siemens Healthineers : Receives CE Mark for the ACUSON AcuNav Volume ICE Catheter

06/02/2021 | 06:17am EDT
  • Siemens Healthineers AcuNav Volume ICE Catheter is the first 4D ICE catheter to receive a CE Mark.
  • AcuNav Volume ICE Catheter improves procedural efficiency for Structural Heart procedures due to the potential reduction of general anesthesia as well as scheduling effort, staffing needs, procedural time, and cost.
  • AcuNav Volume ICE Catheter transforms care delivery by enabling access to Structural Heart procedures for patients with tricuspid regurgitation and other pathologies.

Siemens Healthineers, a global leader in medical technology, announced today that it has received CE Mark for the AcuNav Volume ICE (Intracardiac Echocardiography) catheter, which is a therapy-enabling imaging guide that provides real-time, wide-angle visualization of heart anatomy during Structural Heart and Electrophysiology procedures. AcuNav Volume ICE is the market's first Volume ICE catheter, developed based on 20 years of innovation history in ICE.

Due to the growth of the world population over the age 65 the number of Structural Heart Disease procedures within this population is rapidly expanding. Serving these patients better and faster requires advanced imaging tools to increase procedural efficiency and image quality. With these challenges in mind, Siemens Healthineers developed 4D Volume ICE catheter technology.

'The AcuNav Volume ICE catheter is a pioneering innovation in Structural Heart Disease. It is a result of Siemens Healthineers' focus on designing catheters that meet the needs of interventional cardiologists and electrophysiologists for clinical efficiency with reduced scheduling efforts, staffing needs, procedure time and costs', said Jim Gilmore, Head of Intracardiac Imaging, Siemens Healthineers.

The AcuNav Volume ICE catheter further transforms care delivery by enabling treatment of patients who were not able to previously receive access to Structural Heart procedures. This group includes patients with TOE (transoesophageal echo) or general anesthesia contraindications, as well as some patients suffering from tricuspid regurgitation.

The tricuspid valve can be sufficiently visualized with TOE imaging in only 11% of cases1. Less than 0.5% of 1.6 Million of patients with moderate or severe tricuspid regurgitation are treated annually2.

'Today, we see an increasing focus on the so called 'forgotten valve' - the tricuspid valve. Due to the increasing number of repair and replacement devices for the tricuspid valve, imaging guidance for these procedures is getting more important than ever. With the AcuNav Volume ICE catheter, we are able to clearly visualize the tricuspid valve anatomy from the right heart atrium', said Dr. von Bardeleben, Head of the Center of Structural Heart Disease Interventions and the Heart Valve Center in Mainz, Germany.

'The interest in using 4D Volume ICE came through a patient need', said Dr. Carlos Sanchez, Ohio Health Riverside Methodist Hospital, USA. 'For patients not able to undergo TOE or general anesthesia, we started using 4D ICE for LAAC (Left Atrial Appendage Closure). With 4D Volume ICE you only need one view, and from that view you can reconstruct the whole LAA. Once the device is deployed, you can do all the required measurements to comply with the PASS criteria, which is very important to make this procedure successful'.

Additionally, AcuNav Volume ICE catheter offers potential cost reduction due to reduced cath lab turnaround time and shorter hospital stay, increasing procedural efficiency. Eliminating general anesthesia can cut LAAC procedure and recovery time by 57% compared to TOE3, with potential cost savings of 33%4.

The AcuNav Volume ICE catheter is offered exclusively on the ACUSON SC2000 PRIME ultrasound system, a complete Structural Heart Disease solution delivering advanced visualization and AI-powered quantification with 2D and 4D TTE, TOE, ICE and TrueFusion.


Siemens Healthineers AG published this content on 02 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 June 2021 10:16:01 UTC.

© Publicnow 2021
09:33aSiemens new natural extinguishing agents protect business continuity in criti..
07/22MARKET CHATTER : Swiss Life to Bid for German Biotech-Focused Industrial Park
07/22German Pharma-Park Marburg, home to BioNTech, up for sale -sources
07/22ABB hikes sales outlook, readies electric charger business IPO
07/19Siemens supports first responders in fight against flood
07/19SIEMENS HEALTHINEERS AG : Release of a capital market information
07/19DGAP-CMS : Siemens Healthineers AG: Release of a capital market information
07/16Siemens - eBus charging solution from Siemens paves way for climate-neutral b..
07/15SIEMENS HEALTHINEERS : Barclays reaffirms its Neutral rating
07/14SIEMENS HEALTHINEERS : Morgan Stanley maintains a Buy rating
More news
Sales 2021 17 425 M 20 492 M 20 492 M
Net income 2021 1 602 M 1 884 M 1 884 M
Net Debt 2021 13 750 M 16 171 M 16 171 M
P/E ratio 2021 38,3x
Yield 2021 1,50%
Capitalization 61 608 M 72 472 M 72 454 M
EV / Sales 2021 4,32x
EV / Sales 2022 3,87x
Nbr of Employees 54 300
Free-Float 24,6%
Duration : Period :
Siemens Healthineers AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SIEMENS HEALTHINEERS AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 19
Last Close Price 54,86 €
Average target price 54,56 €
Spread / Average Target -0,55%
EPS Revisions
Managers and Directors
Bernhard Montag Chief Executive Officer
Jochen Schmitz Chief Financial Officer
Ralf Peter Thomas Chairman-Supervisory Board
Thorsten Opderbeck Head-Technology, Trade & Regional Media
A. Gregory Sorensen Member-Supervisory Board
Sector and Competitors